Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety

Journal of Clinical Pharmacology

Volumn 55, Issue S3, 2015, Pages S60-S74

  Xu, Zhenhua ^a   Davis, Hugh M ^a   Zhou, Honghui ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

6 mercaptopurine; azathioprine; biologic therapy; Crohn's disease; drug drug interaction; immunogenicity; immunomodulator; immunosuppression; inflammatory disease; metabolism; methotrexate; monoclonal antibody; pharmacokinetics; rheumatoid arthritis; safety; tumor necrosis factor blocker

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; BIOLOGICAL PRODUCT; CERTOLIZUMAB PEGOL; DRUG ANTIBODY; ETANERCEPT; GOLIMUMAB; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; ARTICLE; BIOLOGICAL THERAPY; CROHN DISEASE; DRUG BILE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; LIVER; LONG TERM CARE; MINIMUM PLASMA CONCENTRATION; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; STEADY STATE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; DRUG INTERACTION; IMMUNOLOGY;

ANTIBODIES, MONOCLONAL; BIOLOGICAL PRODUCTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923354023     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.380     Document Type: Article

References (97)

1. Davidson A, Diamond B,. Autoimmune diseases. N Engl J Med. 2001; 345 (5): 340-350.
2. McInnes IB, Schett G,. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011; 365: 2205-2219.
3. Centers for Disease Control and Prevention. Inflammatory Bowel Disease, 2014. Available at http://www.cdc.gov/ibd/ #Epidemiology of the IBD, Accessed February 23 2014.
4. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med. 2009; 361: 496-509.
5. Walsh GM,. Canakinumab for the treatment of cryopyrin-associated periodic syndromes. Drugs Today (Barc). 2009; 45: 731-735.
6. Scott DL, Wolfe F, Huizinga TW,. Rheumatoid arthritis. Lancet. 2010; 376: 1094-1108.
7. Zhou H, Xu Z, Mascelli MA, Davis HM,. Monoclonal antibodies and antibody-based biotherapeutics in immune-mediated inflammatory diseases, in Pharmaceutical Biotechnology: Fundamentals and Applications (4th Edition), Crommelin DJA, Sindelar RD, Meibohm B, editors, Springer Science; 2013.
8. Chan AC, Carter PJ,. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol. 2010; 10: 301-316.
9. Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ,. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010; 9: 325-338.
10. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000; 343: 1594-1602.
11. St. Clair EW, van der Heijde EW, Smolen DM, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a ramdomized, controlled trial. Arthritis Rheum. 2004; 50: 3432-3443.
12. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008; 371: 1665-1674.
13. AbbVie Inc. Humira® US Prescribing Information, 2013. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125057 s327lbl.pdf. Accessed February 23 2014.
14. Amgen and Pfizer. Enbrel® US prescribing information, 2013. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/103795 s5531lbl.pdf. Accessed February 23 2014.
15. Genentech Inc. Actemra® US prescribing information, 2013. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125276 s092lbl.pdf. Accessed February 23, 2014.
16. GlaxoSmithKline. Benlysta® US prescribing information, Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125370 s047lbl.pdf. Accessed February 23, 2014.
17. Janssen Biotech Inc. Remicade® US prescribing information, 2013. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/103772 s5359lbl.pdf. Accessed February 23, 2014.
18. Janssen Biotech Inc. Simponi® US prescribing information, 2013. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125289 s103lbl.pdf. Accessed February 23, 2014.
19. UCB Inc. Cimzia® US prescribing information, 2013. Available at http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125160 s215lbl.pdf.Accessed February 23, 2014.
20. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999; 354: 1932-1939.
21. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999; 340: 253-259.
22. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. 2004; 50: 1400-1411.
23. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006; 54: 26-37.
24. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56: 1232-1239.
25. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis Rheum. 2009; 60: 2272-2283.
26. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther. 2009; 30: 210-226.
27. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362: 1383-1395.
28. Williams HJ, Willkens RF, Samuelson CO, Jr, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis. Arthritis Rheum. 1985; 28: 721-730.
29. Furst DE, Koehnke R, Burmeister LF, Kohler J, Cargill I,. Increasing methotrexate effect with increasing dose in the treatment of resistant RA. J Rheumatol. 1989; 16: 313-320.
30. Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R,. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995; 37: 674-678.
31. Pearson DC, May GR, Fick GH, Sutherland LR,. Azathioprine and 6-mercaptopurine in Crohn disease: a meta-analysis. Ann Intern Med. 1995; 123: 132-142.
32. Shen DD, Azarnoff DL,. Clinical pharmacokinetics of methotrexate. Clin Pharmacokinet. 1978; 3: 1-13.
33. Nielsen OH, Bjerrum JT, Herfarth H, Rogler G,. Recent advances using immunomodulators for inflammatory bowel disease. J Clin Pharmacol. 2013; 53: 575-588.
34. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH,. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010; 49: 493-507.
35. Zhou H, Mascelli MA,. Mechanisms of monoclonal antibody-drug interactions. Annu Rev Pharmacol Toxicol. 2011; 51: 359-372.
36. Aitken AE, Richardson TA, Morgan ET,. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006; 46: 123-149.
37. Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S,. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011; 89: 735-740.
38. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003; 25: 1700-1721.
39. Chow AT, Earp JC, Gupta M, Hanley W, Hu C, Wang DD, et al. Utility of population pharmacokinetic modeling in the assessment of therapeutic protein-drug interactions. J Clin Pharmacol. 2013. DOI: 10.1002/jcph.240. [Epub ahead of print].
40. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weeklymethotrexate in rheumatoid arthritis. Arthritis Rheum. 1998; 41: 1552-1563.
41. Zhuang Y, Xu Z, Frederick B, et al. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study. Clin Ther. 2012; 34: 77-90.
42. FDA. Clinical pharmacology and biopharmaceutics review for certolizumab pegol (BLA 125160/0). 2006; Available at http://www.accessdata.fda.gov/drugsatfda-docs/nda/2008/125160 s000-ClinPharmR.pdf. Accessed February 27, 2014.
43. Zhou H, Mayer PR, Wajdula J, Fatenejad S,. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J Clin Pharmacol. 2004; 44: 1235-1243.
44. Radstake TR, Svenson M, Eijsbouts AM, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009; 68: 1739-1745.
45. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007; 66: 921-926.
46. Vermeire S, Noman M, Van Assche G, Baert F, D'Haens G, Rutgeerts P,. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut. 2007; 56: 1226-1231.
47. Bunescu A, Seideman P, Lenkei R, Levin K, Egberg N,. Enhanced Fcγ receptor I, αMβ2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. J Rheumatol. 2004; 31: 2347-2355.
48. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004; 363: 675-681.
49. Schellekens H,. The immunogenicity of therapeutic proteins. Discov Med. 2010; 9: 560-564.
50. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
51. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med. 2003; 348: 601-608.
52. West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ,. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther. 2008; 28: 1122-1126.
53. Bartelds GM, Krieckaert CL, Nurmohamed MT, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011; 305: 1460-1468.
54. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP,. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005; 54: 237-241.
55. Benedek TG,. Methotrexate: from its introduction to non-oncologic therapeutics to anti-TNF-α. Clin Exp Rheumatol. 2010; 28: S3-S8.
56. Lennard L,. The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol. 1992; 43: 329-339.
57. Shealy D, Cai A, Staquet K, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs. 2010; 2: [Epub ahead of print].
58. Emery P, Fleischmann R, van der Heijde D, et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum. 2011; 63: 1200-1210.
59. Ordás I, Feagan BG, Sandborn WJ,. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change. Gut. 2011; 60: 1754-1763.
60. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65.
61. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 2007; 357: 228-238.
62. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007; 357: 239-250.
63. Lémann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology. 2006; 130: 1054-1061.
64. D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008; 371: 660-667.
65. Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. Gastroenterology. 2014; 146: 383-391.
66. Van Assche G, Lewis JD, Lichtenstein GR, et al. The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety. Am J Gastroenterol. 2011; 106: 1594-1602.
67. Rosenblum H, Amital H,. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev. 2011; 10: 563-568.
68. Jain A, Singh JA,. Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy. 2013; 5: 265-299.
69. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum. 2005; 52: 3403-3412.
70. Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. Arthritis Rheum. 2006; 54: 1075-1086.
71. Zink A, Manger B, Kaufmann J, et al. Evaluation of the RABBIT risk score for serious infections. Ann Rheum Dis. 2013: 28.
72. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF,. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008; 6: 644-653.
73. Colombel JF, Sandborn WJ, Panaccione R, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis. 2009; 15: 1308-1319.
74. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulator-treated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012; 107: 1051-1063.
75. Wolfe F, Michaud K,. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum. 2007; 56: 1433-1439.
76. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006; 54: 692-701.
77. Salliot C, van der Heijde D,. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis. 2009; 68: 1100-1104.
78. Askling J, Baecklund E, Granath F, et al. Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register. Ann Rheum Dis. 2009; 68: 648-653.
79. Bernstein CN, Blanchard JF, Kliewer E, Wajda A,. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001; 91: 854-862.
80. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL,. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology. 2001; 121: 1080-1087.
81. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE,. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009; 7: 874-881.
82. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD,. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005; 54: 1121-1125.
83. Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011; 9: 36-41.
84. Lichtenstein GR, Hanauer SB, Sandborn WJ,. Management of Crohn's disease in adults. Am J Gastroenterol. 2009; 104: 465-483.
85. Buchner AM, Blonski W, Lichtenstein GR,. Update on the management of Crohn's disease. Curr Gastroenterol Rep. 2011; 13: 465-474.
86. Singh JA, Furst DE, Bharat A, et al. American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012; 64: 625-639.
87. Xu Z, Davis HM, Zhou H,. Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacol Ther. 2013; 137: 225-247.
88. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2013; 73: 492-509.
89. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005; 52: 3381-3390.
90. Smolen JS, Van Der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006; 54: 702-710.
91. Garimella TS, Peng JZ, Beck K, et al. Pharmacokinetics of adalimumab in a long-term investigation of the induction and maintenance of remission in patients with Crohn's disease (CLASSIC I and CLASSIC II) [abstract no. T1133]. Gastroenterology. 2006; 130 (4 Suppl. 2): A-481.
92. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999; 130: 478-486.
93. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000; 343: 1586-1593.
94. Ternant D, Ducourau E, Perdriger A, et al. Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis. Br J Clin Pharmacol. 2014; 78: 118-128.
95. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM,. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011; 33: 946-964.
96. Keystone E, Heijde Dv, Mason D, Jr, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 2008; 58; 3319-3329.
97. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor-α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009; 68: 789-796.